Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody Energy, Ballard Fall
Top Takeaways From BMO's Specialty Pharma Day
The Medicines Co. Loses Angiomax Patent Lawsuit to Hospira - Analyst Blog (Zacks)
Related NVS
Must Watch Stocks for June 29, 2015
The Note Moving Pharma Giants Today
Sector's Smaller Players Show The Way (Seeking Alpha)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters